Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
This volatility comparison pits the dividend aristocrats ETF against the SP500 to help you evaluate relative risk and inform allocation decisions.
20,523 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Stocks of Intel, AMD and Taiwan Semiconductor slid as Bank of America warned that bubble risk may be rising in the AI...
In the first half of 2026, Sandisk towered over the S&P 500. This article explains the drivers behind that outperform...
A Trump-backed memecoin tumbled this week, erasing $3.81 billion in value and affecting nearly million wallets down. ...
Could this chip stock be the next Micron? As AI workloads surge, memory players with strong contract pipelines and he...
Microsoft is not shrinking its ambitions. In this deep dive, we explore how the tech giant aims to reset its gaming d...
Tech stocks regain momentum as data-center spending reshapes the market. Oracle stands out as a potential upside surp...
Bitcoin's on-chain data shows long-term holders selling at a pace of about $280 million per day, the strongest rate s...
New housing data show wages growing faster than home prices, signaling improving affordability. Borrowers may see ste...
A tight group of U.S.-listed power chip stocks built around silicon carbide and GaN technologies are rallying as elec...
XRP remains around the $1 mark as the CLARITY Act stalls in the Senate, raising questions about regulatory clarity an...
Regulators are advancing new crypto rules that could change trading, custody, and enforcement. This guide breaks down...